KROS: Keros Therapeutics, Inc. Stock

by  •  • Comments Off on KROS: Keros Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 548.80
Enterprise Value ($M) -11.13
Book Value ($M) 571.55
Book Value / Share 14.09
Price / Book 0.96
NCAV ($M) 544.56
NCAV / Share 13.43
Price / NCAV 1.01

Profitability (mra)
Return on Invested Capital (ROIC) -0.32
Return on Assets (ROA) -0.39
Return on Equity (ROE) -0.41

Liquidity (mrq)
Quick Ratio 21.45
Current Ratio 21.45

Balance Sheet (mrq) ($M)
Current Assets 588.89
Assets 615.89
Liabilities 44.33
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 3.55
Operating Income -210.83
Net Income -187.35

Cash Flow Statement (mra) ($M)
Cash From Operations -160.87
Cash from Investing -1.93
Cash from Financing 391.82

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
1 day ago 13D/A Pontifax Management 4 G.p. (2015) Ltd. 11.80 1.12
8 days ago 13D ADAR1 Capital Management, LLC 13.29
02-14 13G Alkeon Capital Management Llc 2.70 -26.55
02-07 13G/A Fmr Llc 1.70 -81.82

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 229,023 1,034,996 22.13
2025-04-16 288,131 976,768 29.50
2025-04-15 93,760 704,608 13.31
2025-04-14 407,037 1,502,293 27.09

(click for more detail)

Similar Companies
KALV – KalVista Pharmaceuticals, Inc. KLTO – Klotho Neurosciences, Inc.
KOD – Kodiak Sciences Inc. KYMR – Kymera Therapeutics, Inc.
LGND – Ligand Pharmaceuticals Incorporated


Financial data and stock pages provided by
Fintel.io